US FDA issues CRL for ZS-9 in hyperkalaemia
This announcement contains inside information 17 March 2017 07:00 GMT ASTRAZENECA RECEIVES COMPLETE RESPONSE LETTER FROM US FDA FOR ZS-9 (SODIUM ZIRCONIUM CYCLOSILICATE) FOR HYPERKALAEMIA AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate). Sodium zirconium cyclosilicate is being developed for the treatment of hyperkalaemia by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. Hyperkalaemia is characterised by high potassium